Craig Hallum Increases Eton Pharmaceuticals (NASDAQ:ETON) Price Target to $10.00

Eton Pharmaceuticals (NASDAQ:ETON) had its target price boosted by Craig Hallum from $8.00 to $10.00 in a research report released on Friday morning, Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Separately, HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $9.00 to $11.00 and gave the company a buy rating in a report on Friday.

Eton Pharmaceuticals Price Performance

NASDAQ ETON opened at $7.00 on Friday. The stock has a market capitalization of $179.84 million, a P/E ratio of 175.00 and a beta of 1.31. The business has a 50 day simple moving average of $4.71 and a 200 day simple moving average of $3.93. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $7.07.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The company had revenue of $9.07 million during the quarter, compared to the consensus estimate of $10.00 million. Equities analysts expect that Eton Pharmaceuticals will post -0.15 earnings per share for the current year.

Insider Activity

In other news, major shareholder Opaleye Management Inc. bought 57,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the acquisition, the insider now directly owns 2,660,000 shares in the company, valued at approximately $12,369,000. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 14.89% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC increased its holdings in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $362,000. Thompson Siegel & Walmsley LLC bought a new stake in Eton Pharmaceuticals during the second quarter worth $420,000. Acadian Asset Management LLC raised its position in Eton Pharmaceuticals by 13.7% in the 1st quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after buying an additional 18,898 shares during the last quarter. Finally, Aristides Capital LLC bought a new position in Eton Pharmaceuticals during the 2nd quarter valued at $658,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.